{"id":"W3159335234","doi":"10.2147/ott.s291801","title":"A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies","year":2021,"lang":"en","type":"article","venue":"OncoTargets and Therapy","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Chugai Pharmaceutical; Merck Sharp and Dohme; EMD Serono; Genentech; Plexxikon; Bausch Health; STCube; PharmaMar; European Society for Medical Oncology; Astellas Pharma; Silverback Therapeutics; Daiichi Sankyo Europe; National Cancer Institute; Calithera Biosciences; Aminex Therapeutics; Agios Pharmaceuticals; IFM Therapeutics; Symphogen; Pfizer; Incyte; Boston Pharmaceuticals; Five Prime Therapeutics; Loxo Oncology; Astex Pharmaceuticals; Eli Lilly and Company; National Comprehensive Cancer Network; Principia Biopharma; University of Texas MD Anderson Cancer Center; Puma Biotechnology; National Institutes of Health; BioMarin Pharmaceutical; Regeneron Pharmaceuticals; Baxalta; Immune Deficiency Foundation; Helsinn; Exelixis; Karyopharm Therapeutics; Bristol-Myers Squibb; American Society of Clinical Oncology; Sanofi; Amgen","keywords":"Crizotinib; Pazopanib; Medicine; ROS1; Internal medicine; Oncology; Tyrosine-kinase inhibitor; Progressive disease; Gastroenterology; Pharmacology; Cancer; Sunitinib; Chemotherapy; Lung cancer; Adenocarcinoma","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001223503,0.001600896,0.002270738,0.0004161262,0.000428812,0.00101675,0.00073087,0.0009264218,0.003029672],"category_scores_gemma":[0.0009287694,0.0006024899,0.001095538,0.0005545425,0.0008921496,0.0008430133,0.0004558796,0.003328679,0.000820909],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001259053,"about_ca_system_score_gemma":0.001591581,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001260343,"about_ca_topic_score_gemma":0.003037396,"domain_scores_codex":[0.9995989,0.0001560686,0.00002612341,0.00008828733,0.0000441925,0.00008639725],"domain_scores_gemma":[0.9993399,0.000079382,0.0001144762,0.00003960847,0.00003544316,0.0003910722],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7665145,0.04374528,0.01027363,0.001476095,0.002211856,0.0008896933,0.0004225999,0.003155693,0.05277725,0.0003291174,0.006401054,0.1118032],"study_design_scores_gemma":[0.6423307,0.3357125,0.0140863,0.00004215641,0.000563337,0.0007012902,0.0000541535,0.001474795,0.00264832,0.0001447222,0.00221727,0.00002452051],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9919614,0.002798468,0.0003664026,0.0005523942,0.0001354501,0.001405044,0.0006475424,0.0000806551,0.002052557],"genre_scores_gemma":[0.9933082,0.001478199,0.00103515,0.0004677336,0.0001781706,0.0009113695,0.001454504,0.00001730557,0.001149404],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003029672,"threshold_uncertainty_score":0.01013529,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.00900558308648964,"score_gpt":0.2918006701008566,"score_spread":0.282795087014367,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}